Answers are grounded in this paper and cite their sources.
α-Mangostin (αM) belongs to a bioactive xanthone derivative, having antioxidant and potential neuroprotective properties. However, its therapeutic applications are restricted due to limited aqueous solubility and limited penetration across the blood-brain barrier (BBB) of the brain. The present study aimed to develop αM-loaded polymeric nanoparticles for a intranasal delivery and improved brain availability. αM was initially selected through a multiscale in-silico studies. The optimized αM-PNPs (polylactide-co-glycolide as PLGA nanoparticles) were characterized using the physicochemical, in-vitro , and ex - vivo evaluations, followed by long-term stability studies. I n vivo pharmacokinetics were conducted in rats and a preliminary neuroprotective activity was evaluated in OGD/R-induced BV-2 cells. The in-silico analysis showed a favorable docking score (-9.980 kcal/mol) for αM and formed a stable complex with the PPAR-γ receptor throughout a 200ns MD simulation, supporting its predicted interaction with PPAR-γ. The optimized αM-PNPs exhibited a mean particle size of 232.63 ± 5.03 nm, a zeta potential of -20.9 ± 2.27 mV, an encapsulation efficiency (%EE) of 84.7 ± 3.57%, a drug loading (%DL) of 14.5 ± 1.08%, and a polydispersity index (PDI) of 0.191 ± 0.024. The αM-PNPs exhibited a biphasic drug release profile, with approximately 88% cumulative drug release over 12 h. However, based on the reported regression coefficients, the release profile was best fitted to first-order and Hixson-Crowell models (r² = 0.9976). The steady state permeation flux value ( J ss ) of αM-PNPs (573.98 ± 17.1 µg/h.cm 2 ) was relatively higher than αM-SUS (316.8 ± 10.6 µg/h.cm 2 ), demonstrating an intense modulation of the BBB for improved penetration into the brain. The optimized αM-PNPs demonstrated a satisfactory long-term stability under the controlled storage conditions. αM-PNPs showed enhanced brain drug availability and improved in vitro cytoprotective activity (BV-2) as compared to αM-SUS. Overall, the developed intranasal αM-PNPs represent a promising non-invasive strategy for enhancing nose-to-brain delivery of αM.
No takes yet. Share an insight, caveat, or question.
Pardeshi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: